EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double‐Blind Crossover Trial

Charlotte Vogt iD, Markus Weber, Ursula Schneider, Christoph Neuwirth

Muscle & Nerve · 2025

DOI: 10.1002/mus.28440 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Charlotte Vogt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St Gallen, St Gallen, Gallen, Switzerland. Hauptthemen laut MEDLINE: Quinine, Muscle Cramp, Amyotrophic Lateral Sclerosis. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Swiss ALS foundation, Hänseler AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Many patients with amyotrophic lateral sclerosis (ALS) experience muscle cramps during the course of the disease. This study aimed to evaluate the efficacy of orally administered quinine sulfate for muscle cramps in ALS patients.

Methods

We conducted a randomized, double‐blind, placebo‐controlled crossover trial in ALS patients experiencing daily muscle cramps. After a two‐week run‐in period, patients were assigned to receive 250 mg quinine sulfate once daily, followed by a placebo or vice versa. Each treatment period lasted 2 weeks and was followed by a 4‐week washout period. Patients used a daily diary to rate muscle cramp intensity on the numeric rating scale (NRS) and record muscle cramp frequency. The primary outcome measure was change in cramp intensity; coprimary outcome measures were number of muscle cramps during daytime and nighttime.

Results

Data from four women and three men were included in the analysis, all of whom reported a notable reduction in cramp intensity and frequency, leading them to continue the medication. Quinine sulfate was well‐tolerated, with two patients reporting mild tinnitus. Cramp intensity was significantly reduced by 48% ( p = 0.042). Further, the number of daytime muscle cramps declined significantly ( p = 0.024).

Discussion

Our findings suggest the potential efficacy of quinine sulfate in reducing muscle cramp intensity and frequency in ALS patients. However, the small sample size ( n = 7) limits generalizability. Larger, multicenter studies are needed to confirm these results and fully assess its safety, serious adverse events, and therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinineMuscle CrampAmyotrophic Lateral SclerosisHumansDouble-Blind MethodMaleFemaleCross-Over StudiesMiddle AgedAgedAdultTreatment OutcomeMuscle Relaxants, Central

Stichwörter der Autor:innen

ALSefficacymuscle crampsplacebo‐controlled trialquinine sulfate

Substanzen

QuinineMuscle Relaxants, Central

Autor:innen und Institutionen

  • Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St Gallen, St Gallen, Gallen, Switzerland.

ORCID-Profile: Charlotte Vogt

Förderung

  • Swiss ALS foundation
  • Hänseler AG

Zitieren

APA

Vogt, C., Weber, M., Schneider, U., & Neuwirth, C. (2025). Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double‐Blind Crossover Trial. Muscle & Nerve. https://doi.org/10.1002/mus.28440

Vancouver

Vogt C, Weber M, Schneider U, Neuwirth C. Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double‐Blind Crossover Trial. Muscle & Nerve. 2025. doi:10.1002/mus.28440

BibTeX
@article{Vogt2025,
  author = {Vogt, Charlotte and Weber, Markus and Schneider, Ursula and Neuwirth, Christoph},
  title = {Quinine Sulfate for Muscle Cramps in Amyotrophic Lateral Sclerosis: A Randomized, Double‐Blind Crossover Trial},
  journal = {Muscle & Nerve},
  year = {2025},
  doi = {10.1002/mus.28440}
}
Kostenlos starten →